AMG 596, a novel anti-egfrviii bispecific t cell engager (bite®) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM)

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
JournalNeuro-Oncology
Year 2019
This article has no abstract
Epistemonikos ID: df50cee0997f899d32e7852180d4856d6d8c6b4a
First added on: Feb 11, 2025